Calithera Biosciences

January 04, 2021

Unhappy new year for Calithera

The company welcomes in 2021 with the failure of a pivotal study of its pipeline lead, telaglenastat.

December 18, 2020

First-quarter catalysts for the smaller players

Important data releases are on the cards for Rhythm, Wave and Supernus, among others.

September 30, 2020

Clinical data focus for the smallest players

Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.

September 05, 2019

Esmo 2019 preview – Parps on parade

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

October 11, 2017

World Lung and SITC – two more doses of oncology

January 31, 2017

Incyte gives Calithera a new lease of life

June 10, 2016

Asco event analyser – 2016’s winners and losers

July 03, 2015

Sector’s smaller players show the way

June 03, 2015

Asco Event Analyzer – 2015’s winners and losers

April 08, 2015

Therapy focus – Potential for progress in mesothelioma is on the horizon

January 05, 2015

Strong quarter sees 2014 race to record IPO haul

Load More